Clonal and microclonal mutational heterogeneity in high hyperdiploid acute lymphoblastic leukemia

Keyphrases

• Acute Lymphoblastic Leukemia 100%
• B-cell Acute Lymphoblastic Leukemia (B-ALL) 100%
• FMS-like Tyrosine Kinase 3 (FLT3) 100%
• PTPN11 100%
• Mutational Heterogeneity 100%
• Hyperdiploidy 100%
• Hotspot mutation 100%
• DOT1L 100%
• High Hyperdiploid 100%
• Novel Therapeutic Targets 50%
• Novel Therapeutics 50%
• Tumor 50%
• Functional Consequences 50%
• Microheterogeneity 50%
• Regulatory Genes 50%
• Epigenetics 50%
• Receptor Tyrosine Kinase 50%
• Leukemogenesis 50%
• Phosphorylation 50%
• Novel mutation 50%
• Tumor Heterogeneity 50%
• Codon 12 50%
• Activating mutation 50%
• Tumor Samples 50%
• Relevant Genes 50%
• Epigenetic Dysregulation 50%
• Codon 13 50%
• RAS-MAPK Pathway 50%
• Damaging mutations 50%
• Pathway mutation 50%
• SHP2 50%
• Driver Genes 50%
• Targeted Deep Sequencing 50%
• High Hyperdiploidy 50%
• ROS1 50%
• Functional Cooperation 50%
• Clinical Outcomes 50%
• Encoded Protein 50%
• Mutant Allele Frequency 50%
• Treatment-related Morbidity 50%
• Ongoing Formation 50%

Biochemistry, Genetics and Molecular Biology

• KRAS 100%
• PTPN11 66%
• DOT1L 66%
• B Cell 66%
• Signal Transduction 33%
• ROS1 33%
• Locus Control Region 33%
• Cooperation 33%
• Allele 33%
• Cytogenetics 33%
• Morbidity 33%
• MAPK Signaling 33%
• Codon 33%
• Receptor Tyrosine Kinase 33%
• Deep Sequencing 33%
• phosphorylation 33%